Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) subsidiary Guangzhou Baiyunshan Zhongyi Pharmaceutical received an updated drug manufacturing license from the Guangdong Provincial Drug Administration in China, according to a Wednesday filing with the Shanghai bourse.
The updated license covers the change of the person in charge of production, as well as the removal of a production facility.
The changes will not affect Zhongyi Pharmaceutical's production.